Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Hold” by Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received a consensus recommendation of “Hold” from the nine analysts that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $10.14.

Several equities research analysts recently commented on NMRA shares. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. William Blair cut Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 10th. Bank of America reduced their target price on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a report on Monday, January 6th. Stifel Nicolaus downgraded Neumora Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $6.00 to $2.00 in a research note on Friday, March 7th. Finally, Guggenheim cut Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, March 7th.

Neumora Therapeutics Stock Performance

Shares of NMRA opened at $1.20 on Tuesday. The company’s 50-day simple moving average is $1.70 and its 200-day simple moving average is $7.81. Neumora Therapeutics has a 1 year low of $1.12 and a 1 year high of $17.19. The stock has a market capitalization of $194.37 million, a PE ratio of -0.64 and a beta of 2.59.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, sell-side analysts predict that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Institutional Trading of Neumora Therapeutics

Several institutional investors have recently made changes to their positions in NMRA. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Neumora Therapeutics during the 4th quarter worth approximately $61,000. PNC Financial Services Group Inc. purchased a new position in Neumora Therapeutics in the fourth quarter valued at about $64,000. Quantbot Technologies LP acquired a new position in shares of Neumora Therapeutics during the fourth quarter worth about $92,000. PEAK6 LLC acquired a new position in Neumora Therapeutics during the 4th quarter worth approximately $117,000. Finally, EntryPoint Capital LLC acquired a new position in Neumora Therapeutics during the 4th quarter worth approximately $135,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.